IPTACOPAN ASH UPDATE

As a potent, selective factor B inhibitor, iptacopan has the potential to be practice-changing, the new standard of care in PNH Addresses both intravascular and extravascular hemolysis Superior in PNH patients with residual anemia despite prior anti-C5 treatment (APPLY) ■ Normalized hemoglobin levels ■ Reduced need for transfusions ■ Reduced patient-reported fatigue ■ Favorable safety with no serious breakthrough hemolysis Clinically meaningful Hb increases in treatment- naive patients (APPOINT) Safety profile consistent with APPLY-PNH Significant QoL benefits as the first oral monotherapy 23 IPTACOPAN ASH UPDATE | DECEMBER 13, 2022 NOVARTIS | Reimagining Medicine

View entire presentation